Carregant...
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
Breast cancer development in BRCA1/2 mutation carriers is a net consequence of cell-autonomous and cell nonautonomous factors which may serve as excellent targets for cancer prevention. In light of our previous data we sought to investigate the consequences of the BRCA-mutation carrier state on RANK...
Guardat en:
Publicat a: | EBioMedicine |
---|---|
Autors principals: | , , , , , , , , , , , , , , |
Format: | Artigo |
Idioma: | Inglês |
Publicat: |
Elsevier
2015
|
Matèries: | |
Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4634624/ https://ncbi.nlm.nih.gov/pubmed/26629528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2015.08.037 |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|